GSK Investigational Site

Guiyang, Guizhou 550000

0 studies enrolling now · 1 studies all time

What they study most

Neoplasms, Head and Neck

Studies at this site

• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early